TriLink Biotechnologies Announces Supplier Agreement with Applied Biosystems
News Nov 08, 2007
TriLink Biotechnologies announced that it has signed a service agreement with Applied Biosystems to supply reagents for Applied Biosystems' recently launched next-generation genetic analysis platform, the SOLiD™ System.
As part of the agreement, TriLink is providing Applied Biosystems with custom dye-labeled oligonucleotides, or chemically synthesized nucleotides, which are used as part of the DNA sequencing process.
"Working with best-in-class suppliers like TriLink has enabled us to develop the most robust, accurate, and highest-throughput genetic analysis platform available to help our customers take advantage of the emerging applications for next-generation DNA sequencing," said Kim Caple, vice president and general manager for Applied Biosystems' next-generation sequencing business.
"We are proud that Applied Biosystems has chosen TriLink to be the supplier of the oligonucleotides used in the SOLiD™ system," said TriLink CEO, Dr. Richard Hogrefe.
There are hundreds of thousands of structural variants (SVs) in the human genome that are hard to identify than single nucleotide variants. Researchers have used a full suite of genomic technologies to analyze the number of SVs in three individuals, and the results present as the most comprehensive catalog of SVS to date.READ MORE